187 related articles for article (PubMed ID: 37473802)
1. Escherichia coli Nissle 1917 ghosts alleviate inflammatory bowel disease in zebrafish.
Chen H; Lei P; Ji H; Ma J; Fang Y; Yu H; Du J; Qu L; Yang Q; Luo L; Zhang K; Wu W; Jin L; Sun D
Life Sci; 2023 Sep; 329():121956. PubMed ID: 37473802
[TBL] [Abstract][Full Text] [Related]
2. Engineered probiotics with sustained release of interleukin-2 for the treatment of inflammatory bowel disease after oral delivery.
Li M; Liu N; Zhu J; Wu Y; Niu L; Liu Y; Chen L; Bai B; Miao Y; Yang Y; Chen Q
Biomaterials; 2024 Sep; 309():122584. PubMed ID: 38735180
[TBL] [Abstract][Full Text] [Related]
3. Programmable probiotics modulate inflammation and gut microbiota for inflammatory bowel disease treatment after effective oral delivery.
Zhou J; Li M; Chen Q; Li X; Chen L; Dong Z; Zhu W; Yang Y; Liu Z; Chen Q
Nat Commun; 2022 Jun; 13(1):3432. PubMed ID: 35701435
[TBL] [Abstract][Full Text] [Related]
4. Beneficial effects resulting from oral administration of
Souza ELS; Campos CLV; Reis DC; Cassali GD; Generoso SV; Cardoso VN; Azevedo V; Medeiros JD; Fernandes GR; Nicoli JR; Martins FS
Benef Microbes; 2020 Dec; 11(8):779-790. PubMed ID: 33191778
[TBL] [Abstract][Full Text] [Related]
5. Enhanced anti-proliferative efficacy of epothilone B loaded with Escherichia coli Nissle 1917 bacterial ghosts on the HeLa cells by mitochondrial pathway of apoptosis.
Zhu W; Hao L; Liu X; Borrás-Hidalgo O; Zhang Y
Drug Dev Ind Pharm; 2018 Aug; 44(8):1328-1335. PubMed ID: 29521115
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo uptake study of Escherichia coli Nissle 1917 bacterial ghosts: cell-based delivery system to target ocular surface diseases.
Stein E; Inic-Kanada A; Belij S; Montanaro J; Bintner N; Schlacher S; Mayr UB; Lubitz W; Stojanovic M; Najdenski H; Barisani-Asenbauer T
Invest Ophthalmol Vis Sci; 2013 Sep; 54(9):6326-33. PubMed ID: 23920373
[TBL] [Abstract][Full Text] [Related]
7. Polyphenolic Nanoparticle-Modified Probiotics for Microenvironment Remodeling and Targeted Therapy of Inflammatory Bowel Disease.
Hu Q; Li J; Wang T; Xu X; Duan Y; Jin Y
ACS Nano; 2024 May; 18(20):12917-12932. PubMed ID: 38720520
[TBL] [Abstract][Full Text] [Related]
8. Prospective and challenges of live bacterial therapeutics from a superhero
Effendi SSW; Ng IS
Crit Rev Microbiol; 2023 Sep; 49(5):611-627. PubMed ID: 35947523
[No Abstract] [Full Text] [Related]
9. Escherichia coli Nissle 1917 bacterial ghosts retain crucial surface properties and express chlamydial antigen: an imaging study of a delivery system for the ocular surface.
Montanaro J; Inic-Kanada A; Ladurner A; Stein E; Belij S; Bintner N; Schlacher S; Schuerer N; Mayr UB; Lubitz W; Leisch N; Barisani-Asenbauer T
Drug Des Devel Ther; 2015; 9():3741-54. PubMed ID: 26229437
[TBL] [Abstract][Full Text] [Related]
10. The effect of probiotic Escherichia coli strain Nissle 1917 lipopolysaccharide on the 5-aminosalicylic acid transepithelial transport across Caco-2 cell monolayers.
Stětinová V; Smetanová L; Kholová D; Květina J; Svoboda Z; Zídek Z; Tlaskalová-Hogenová H
Gen Physiol Biophys; 2013 Sep; 32(3):371-80. PubMed ID: 23846256
[TBL] [Abstract][Full Text] [Related]
11. Escherichia coli strain Nissle 1917 ameliorates experimental colitis by modulating intestinal permeability, the inflammatory response and clinical signs in a faecal transplantation model.
Souza ÉL; Elian SD; Paula LM; Garcia CC; Vieira AT; Teixeira MM; Arantes RM; Nicoli JR; Martins FS
J Med Microbiol; 2016 Mar; 65(3):201-210. PubMed ID: 26758971
[TBL] [Abstract][Full Text] [Related]
12. Reductase-Labile Peptidic Supramolecular Hydrogels Aided in Oral Delivery of Probiotics.
Chen J; Zhang P; Wu C; Yao Q; Cha R; Gao Y
ACS Appl Mater Interfaces; 2023 Jul; 15(26):31214-31223. PubMed ID: 37339324
[TBL] [Abstract][Full Text] [Related]
13. Nattokinase enhances the preventive effects of Escherichia coli Nissle 1917 on dextran sulfate sodium-induced colitis in mice.
Liang M; Zhang J; Yang Y; Xia Y; Liu L; Liu L; Wang Q; Gao X
World J Microbiol Biotechnol; 2022 Nov; 39(1):8. PubMed ID: 36350434
[TBL] [Abstract][Full Text] [Related]
14. Breaking barriers: bacterial-microalgae symbiotic systems as a probiotic delivery system.
Huang H; Liu X; Lang Y; Cui J; Zhong D; Zhou M
J Nanobiotechnology; 2024 Jun; 22(1):371. PubMed ID: 38918805
[TBL] [Abstract][Full Text] [Related]
15. Probiotic
Teng G; Liu Z; Liu Y; Wu T; Dai Y; Wang H; Wang W
Front Microbiol; 2022; 13():819336. PubMed ID: 35602072
[TBL] [Abstract][Full Text] [Related]
16. Encapsulation of Escherichia coli strain Nissle 1917 in a chitosan-alginate matrix by combining layer-by-layer assembly with CaCl
Luo X; Song H; Yang J; Han B; Feng Y; Leng Y; Chen Z
Colloids Surf B Biointerfaces; 2020 May; 189():110818. PubMed ID: 32018138
[TBL] [Abstract][Full Text] [Related]
17. The administration of Escherichia coli Nissle 1917 ameliorates irinotecan-induced intestinal barrier dysfunction and gut microbial dysbiosis in mice.
Wang Y; Sun L; Chen S; Guo S; Yue T; Hou Q; Feng M; Xu H; Liu Y; Wang P; Pan Y
Life Sci; 2019 Aug; 231():116529. PubMed ID: 31173781
[TBL] [Abstract][Full Text] [Related]
18. Modified Prebiotic-Based "Shield" Armed Probiotics with Enhanced Resistance of Gastrointestinal Stresses and Prolonged Intestinal Retention for Synergistic Alleviation of Colitis.
Xie A; Ji H; Liu Z; Wan Y; Zhang X; Xiong H; Nie SP; Wan H
ACS Nano; 2023 Aug; 17(15):14775-14791. PubMed ID: 37477584
[TBL] [Abstract][Full Text] [Related]
19. Probiotic
Zhao Z; Xu S; Zhang W; Wu D; Yang G
Food Funct; 2022 Jun; 13(11):5914-5924. PubMed ID: 35583304
[No Abstract] [Full Text] [Related]
20. An Engineered Probiotic Produces a Type III Interferon IFNL1 and Reduces Inflammations in
Chua KJ; Ling H; Hwang IY; Lee HL; March JC; Lee YS; Chang MW
ACS Biomater Sci Eng; 2023 Sep; 9(9):5123-5135. PubMed ID: 36399014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
